MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Otonomy Company Profile (NASDAQ:OTIC)

Consensus Ratings for Otonomy (NASDAQ:OTIC) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $32.40 (107.96% upside)

Analysts' Ratings History for Otonomy (NASDAQ:OTIC)
Show:
DateFirmActionRatingPrice TargetActions
5/26/2016WallachBeth CapitalInitiated CoverageBuy$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/22/2016Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/9/2015Bank of AmericaUpgradeNeutral -> Buy$31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/13/2015JPMorgan Chase & Co.Initiated CoverageHold$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/10/2015Sanford C. BernsteinUpgradeMarket Perform -> Outperform$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/4/2015SunTrustInitiated CoverageBuy$47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/4/2015Cowen and CompanyInitiated CoverageOutperform$55.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/8/2014Barrington ResearchInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Otonomy (NASDAQ:OTIC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
3/7/2016Q4($0.95)($0.87)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.83)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q116($0.67)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115($0.53)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2015Q415($0.64)($0.46)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Otonomy (NASDAQ:OTIC)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.79)($0.79)($0.79)
Q2 20161($0.92)($0.92)($0.92)
Q3 20161($0.93)($0.93)($0.93)
Q4 20161($0.96)($0.96)($0.96)
(Data provided by Zacks Investment Research)
Dividend History for Otonomy (NASDAQ:OTIC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Otonomy (NASDAQ:OTIC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/21/2015Carl LebelinsiderSell21,250$28.04$595,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2015Paul E. CayerinsiderSell3,000$29.70$89,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015David Allen WeberCEOSell5,208$27.25$141,918.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2015Robert Michael Savel IIinsiderSell5,000$26.00$130,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2015Chau Quang KhuongDirectorSell67,106$28.93$1,941,376.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2015Orbimed Advisors LlcDirectorSell200,800$28.56$5,734,848.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2015Chau Quang KhuongDirectorSell138,398$28.62$3,960,950.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Paul E. CayerinsiderSell3,000$28.69$86,070.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015David Allen WeberCEOSell5,208$28.57$148,792.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2015David Allen WeberCEOSell10,416$30.95$322,375.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015David Allen WeberCEOSell5,208$24.95$129,939.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/11/2015Paul E. CayerCFOSell3,000$24.95$74,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Carl LebelinsiderSell21,250$24.36$517,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2015Paul E. CayerCFOSell3,000$24.95$74,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015David Allen WeberCEOSell5,216$24.95$130,139.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Robert Michael Savel IIinsiderSell5,000$23.98$119,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Robert Michael Savel IIInsiderSell25,000$23.73$593,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2014A/S NovoInsiderBuy15,690$15.50$243,195.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014A/S NovoInsiderBuy171,875$16.00$2,750,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Jay LichterDirectorSell50,001$16.00$800,016.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Otonomy (NASDAQ:OTIC)
DateHeadline
06/23/16 08:22 AMStrong Buy Calls Count For Otonomy, Inc. (NASDAQ:OTIC) At 4 - Investor Newswire
06/23/16 08:22 AMRecently Issued Stock Ratings For Otonomy, Inc. (NASDAQ:OTIC) - Fiscal Standard
06/22/16 03:32 PMOTONOMY, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/20/16 07:18 AMThis Weeks Broker Views For Otonomy, Inc. (NASDAQ:OTIC) - Fiscal Standard
06/16/16 09:54 AMMarket Movers: Verastem, Inc. (NASDAQ:VSTM), Otonomy, Inc. (NASDAQ:OTIC), Helios and Matheson Analytics Inc ... - KC Register
06/11/16 08:32 AMOtonomy (OTIC) Enrolls First Patient in Single OTIPRIOTM Phase 3 cTrial
06/09/16 06:49 AMOtonomy Initiates Patient Enrollment in Single Phase 3 Clinical Trial of OTIPRIO™ in Patients with Acute Otitis Externa - [at noodls] - SAN DIEGO, June 09, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders ...
06/08/16 06:04 PMOTONOMY INC. (NASDAQ:OTIC) Financial Condition Compared to S&P 500 - CML News
06/04/16 05:44 PMAre Analysts Bearish Otonomy Inc (NASDAQ:OTIC) After Last Week? - HNN
06/03/16 08:35 AMWallachBeth Initiates Coverage on Otonomy Inc to Buy - Trade Calls - WallachBeth Initiates Coverage on Otonomy Inc to BuyTrade CallsWallachBeth Initiates Coverage on Otonomy Inc(NASDAQ:OTIC). The shares have been rated Buy. The rating by WallachBeth was issued on May 26, 2016. Otonomy Inc (OTIC) made into the market gainers list on Wednesdays trading session with the shares ...
06/02/16 06:04 PMStock Review and Earnings Check on Otonomy, Inc. (NASDAQ:OTIC) - HNN - Stock Review and Earnings Check on Otonomy, Inc. (NASDAQ:OTIC)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Otonomy, Inc. (NASDAQ:OTIC) to ...and more »
06/02/16 06:04 PMOtonomy, Inc. (NASDAQ:OTIC) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Otonomy, Inc. (NASDAQ:OTIC) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Otonomy, Inc. (NASDAQ:OTIC). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...Stock in a Downward Trend: Otonomy, Inc. (NASDAQ:OTIC)Franklin IndependentCurrent Price Targets For Otonomy, Inc. (NASDAQ:OTIC)Risers & FallersOtonomy, Inc. (NASDAQ:OTIC): Price Target ProjectionsNews TribuneThe Postall 5 news articles »
06/02/16 08:40 AMNews Sentiment For Otonomy, Inc. (NASDAQ:OTIC) - Investor Newswire - News Sentiment For Otonomy, Inc. (NASDAQ:OTIC)Investor NewswireOtonomy, Inc. (NASDAQ:OTIC) Average broker stands at 1.4 while it was 1.4 three months ago. The quarterly report of Otonomy, Inc. (NASDAQ:OTIC) can be made public close to 2016-08-10. It is estimated by the recent update released by the company.and more »
06/01/16 07:16 AMOtonomy, Inc. breached its 50 day moving average in a Bullish Manner : OTIC-US : June 1, 2016 -
05/31/16 10:19 AMShare Rating Focus on Otonomy, Inc. (NASDAQ:OTIC) - HNN - Share Rating Focus on Otonomy, Inc. (NASDAQ:OTIC)HNNPresently, Wall Street analysts have given a consensus stock rating of 1.4 on shares of Otonomy, Inc. (NASDAQ:OTIC). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research. This consensus number is ...and more »
05/30/16 12:39 PMOtonomy Incorporated (NASDAQ:OTIC) Sellers Covered 0.39% of Their Shorts - HNN - Otonomy Incorporated (NASDAQ:OTIC) Sellers Covered 0.39% of Their ShortsHNNThe short interest to Otonomy Incorporated's float is 9.31%. The stock increased 0.84% or $0.12 on May 27, hitting $14.33. About 107,751 shares traded hands. Otonomy Inc (NASDAQ:OTIC) has declined 30.13% since October 22, 2015 and is downtrending.and more »
05/30/16 12:39 PMOtonomy, Inc. (NASDAQ:OTIC) Broker Price Targets For The Coming Week - Share Trading News - Otonomy, Inc. (NASDAQ:OTIC) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Otonomy, Inc. (NASDAQ:OTIC). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...Weekly Research Analysts' Ratings Updates for Otonomy (OTIC)Let Me Know About Thisall 2 news articles »
05/27/16 11:45 AMEarnings Review and Stock Rundown for Otonomy, Inc. (NASDAQ:OTIC) - Wall Street Hints and News - Earnings Review and Stock Rundown for Otonomy, Inc. (NASDAQ:OTIC)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Otonomy, Inc. (NASDAQ:OTIC) to post ...and more »
05/26/16 08:58 AMCoverage initiated on Otonomy by WallachBeth -
05/20/16 06:53 AMOtonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO™ - [at noodls] - SAN DIEGO, May 20, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders ...
05/16/16 07:02 AMOtonomy Announces OTIPRIO™ Data Presentation and Symposium at Combined Otolaryngology Spring Meetings - [at noodls] - SAN DIEGO, May 16, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders ...
05/09/16 03:38 PMOtonomy Reports First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders ...
05/05/16 06:30 AMOtonomy to Present at the Bank of America Merrill Lynch Healthcare Conference - [GlobeNewswire] - SAN DIEGO, May 05, 2016-- Otonomy, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced that ...
04/18/16 06:41 AMOtonomy Announces Phase 3 Clinical Trial Plan for OTIPRIO™ in Otitis Externa Patients Based on Successful End-of-Phase 2 Review by FDA - [at noodls] - SAN DIEGO, April 18, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders ...
04/08/16 10:28 AMEdited Transcript of OTIC earnings conference call or presentation 7-Mar-16 9:30pm GMT -
04/05/16 07:47 AMWhy You Shouldn't Bet Against Otonomy (OTIC) Stock -
03/23/16 06:43 AMOtonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Ménière’s Disease - [at noodls] - SAN DIEGO, March 23, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders ...
03/14/16 11:27 AMNews Buzz: Halliburton Company (NYSE:HAL), Otonomy, Inc. (NASDAQ:OTIC), Merck & Co. Inc. (NYSE:MRK), Biogen ... - KC Register - News Buzz: Halliburton Company (NYSE:HAL), Otonomy, Inc. (NASDAQ:OTIC), Merck & Co. Inc. (NYSE:MRK), Biogen ...KC RegisterOtonomy, Inc. (NASDAQ:OTIC) traded 267916 shares and its share price advanced 4.46% to close at $16.17. Company has 0.10% insider ownership. Otonomy, Inc. (NASDAQ:OTIC) quarterly performance is -37.62% while its year to date (YTD) performance ...
03/11/16 12:04 PMOTONOMY, INC. Financials -
03/07/16 03:41 PMOtonomy reports 4Q loss -
03/07/16 03:30 PMOtonomy Inc Earnings Call scheduled for 4:30 pm ET today -
03/07/16 03:09 PMOTONOMY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
03/07/16 03:09 PMOTONOMY, INC. Files SEC form 10-K, Annual Report -
03/07/16 06:07 AMQ4 2015 Otonomy Inc Earnings Release - After Market Close -
03/03/16 06:30 AMOtonomy Initiates Phase 2 Clinical Trial of OTIPRIO™ in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes - [GlobeNewswire] - SAN DIEGO, March 03, 2016-- Otonomy, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced ...
03/02/16 06:30 AMOtonomy Announces Commercial Availability of OTIPRIO™ - [GlobeNewswire] - SAN DIEGO, March 02, 2016-- Otonomy, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced ...
02/29/16 06:30 AMOtonomy to Present at Cowen and Company Health Care Conference - [GlobeNewswire] - SAN DIEGO, Feb. 29, 2016-- Otonomy, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced ...
02/26/16 06:30 AMOtonomy to Report Fourth Quarter and Full Year 2015 Financial Results and Provide Corporate Update - [GlobeNewswire] - SAN DIEGO, Feb. 26, 2016-- Otonomy, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced ...
02/13/16 01:24 PMCan Otonomy, Inc. (NASDAQ:OTIC) Record A Positive Move? - Stocks Daily - Can Otonomy, Inc. (NASDAQ:OTIC) Record A Positive Move?Stocks DailyZacks Research report highlights that Otonomy, Inc. (NASDAQ:OTIC) shares can make a high of $55 in the coming year. Zacks carried out a poll of leading brokerage firms and had set a price target of $41.6. This represents the view of 5 brokerages that ...and more »
02/11/16 01:15 PMOtonomy Inc (OTIC) is Trading Higher on Unusual Volume for February 10 - Equities.com - Otonomy Inc (OTIC) is Trading Higher on Unusual Volume for February 10Equities.comOtonomy Inc (OTIC) experienced unusually high volume on Feb. 10, as the stock gained 3.83% to a closing price of $13.28. The stock saw 915,137 shares trade hands over the course of the day on 1,692 trades. Given that the stock's average daily volume ...
02/11/16 01:15 PMCommit To Buy Otonomy At $10, Earn 11.7% Annualized Using Options - Investors considering a purchase of Otonomy Inc (OTIC) stock, but cautious about paying the going market price of $13.45/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in ...
02/04/16 12:13 PMOtonomy Inc Just Reaches 52-Week Low? - WallStreet.org - Otonomy Inc Just Reaches 52-Week Low?WallStreet.orgThe stock of Otonomy Inc (NASDAQ:OTIC) hit a new 52-week low and has $12.44 target or 12.00% below today's $14.14 share price. The 5 months bearish chart indicates high risk for the $433.86 million company. The 1-year low was reported on Feb, 4 by ...and more »
02/04/16 12:13 PMToday Otonomy Inc Stock Reaches All-Time Low - WallStreet.org - Today Otonomy Inc Stock Reaches All-Time LowWallStreet.orgThe stock of Otonomy Inc (NASDAQ:OTIC) reached all time low today, Feb, 4 and still has $12.73 target or 10.00% below today's $14.14 share price. This indicates more downside for the $433.86M company. This technical setup was reported by Barchart.com.
02/03/16 07:06 PMOtonomy, Inc. (NASDAQ:OTIC): Quarterly Earnings Update - Investor Newswire - Otonomy, Inc. (NASDAQ:OTIC): Quarterly Earnings UpdateInvestor NewswireAs per the research firms that were included in Zacks Research survey, Otonomy, Inc. (NASDAQ:OTIC) is projected an EPS of $-1.21 for last quarter. The firm can release the earnings report on or around 2016-03-16. Since the ratings compiled by Zacks ...and more »
02/01/16 11:43 AMCompany Shares of Otonomy, Inc. (NASDAQ:OTIC) Drops by -11.24% - Analyst Rating Reports - Company Shares of Otonomy, Inc. (NASDAQ:OTIC) Drops by -11.24%Analyst Rating ReportsOtonomy, Inc. (NASDAQ:OTIC) has lost 11.24% during the past week and dropped 46.23% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 12.77%. Otonomy, Inc. (NASDAQ:OTIC) has ...Analysts Set Otonomy Inc (NASDAQ:OTIC) Target Price at $35.50EMQEPS Estimate Of Otonomy, Inc. (NASDAQ:OTIC)Vanguard Tribuneall 5 news articles »
01/29/16 11:49 AMAnalyst Price Target on Otonomy, Inc. - Market Briefing - Analyst Price Target on Otonomy, Inc.Market BriefingOtonomy, Inc. (NASDAQ:OTIC): 5 Analyst have given the stock of Otonomy, Inc. (NASDAQ:OTIC) a near short term price target of $41.6. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean ...
01/26/16 11:58 AMOtonomy (OTIC) Announces Publication of Preclinical OTO-104 Data in Cisplatin-Induced Hearing Loss - StreetInsider.com - Otonomy (OTIC) Announces Publication of Preclinical OTO-104 Data in Cisplatin-Induced Hearing LossStreetInsider.comOtonomy, Inc. (NASDAQ: OTIC)announced the publication in Audiology & Neurotology of a preclinical study titled, “The Sustained-Exposure Dexamethasone Formulation OTO-104 Offers Effective Protection against Cisplatin-Induced Hearing Loss”. This study ...Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced ...Virtual-Strategy Magazineall 2 news articles »
01/26/16 06:19 AMOtonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss - [at noodls] - , (GLOBE NEWSWIRE) -- , Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced ...
01/25/16 11:06 AMCompany Shares of Otonomy, Inc. (NASDAQ:OTIC) Drops by -1.52% - The Daily Rover - Company Shares of Otonomy, Inc. (NASDAQ:OTIC) Drops by -1.52%The Daily RoverOtonomy, Inc. (NASDAQ:OTIC) has lost 1.52% during the past week and dropped 39.77% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 2.9%. Otonomy, Inc. (NASDAQ:OTIC) has ...
01/25/16 06:17 AMCollegium Appoints Ted Schroeder to Board of Directors - [at noodls] - , (GLOBE NEWSWIRE) -- (Nasdaq:COLL) today announced the appointment of to its board of directors. Mr. Schroeder led specialty pharmaceutical company from its founding until its acquisition by for in 2014. ...
About Otonomy

Otonomy logoOtonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company has developed a technology referred to as sustained-exposure that is designed to deliver drug that is retained in the ear for an extended period of time following a local administration. Its product candidates include OTIPRIO, OTO-104 and OTO-311. The Company's product candidate, OTIPRIO, is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery. Its product candidate, OTO-104, is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. The Company's product candidate, OTO-311, is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OTIC
  • CUSIP:
Key Metrics:
  • Previous Close: $16.25
  • 50 Day Moving Average: $14.15
  • 200 Day Moving Average: $16.83
  • P/E Ratio: N/A
  • P/E Growth: -0.21
  • Market Cap: $469.16M
  • Current Quarter EPS Consensus Estimate: $-3.56 EPS
Additional Links:
Otonomy (NASDAQ:OTIC) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha